Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2000-05-23
2003-10-21
Naff, David M. (Department: 1651)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C435S176000, C514S002600, C530S402000, C530S811000
Reexamination Certificate
active
06635269
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a method for the immobilization of mediator molecules on surfaces of metallic or ceramic materials which are used for implants such as artificial joints or also microimplants, for example so-called stents, as well as implants produced according to the method.
2. Description of the Related Art
The implantation of artificial joints or bones has gained increasing importance in recent years, for example in the treatment of joint dysplasias or joint dislocations or in sicknesses resulting from joint attrition as a result of improper joint positioning. The function of the implants and the materials used for their production, which, in addition to metals such as titanium or metal alloys, can also include ceramics or synthetic materials such as teflon, have been continually improved, so that following a successful healing process, implants exhibit lifetimes of 10 years in 90-95% of all cases. Yet despite this progress and these improved operational methods, an implantation still remains a difficult and strenuous operation, particularly since it is associated with a long process of healing-in of the implants, often including month-long stays in clinics and health resorts, including rehabilitation measures. In addition to the pain, the length of the treatment period and the separation from familiar surroundings represent heavy stresses for the affected patients. In addition, the long healing process incurs high personal and treatment costs due to the required intensive care.
The understanding of the molecular-lever processes required for a successful growing-in of an implant has markedly increased in recent years. Structural compatibility and surface compatibility are crucial for the tissue tolerability of an implant. Biocompatibility in a narrower sense depends only on the surface. Proteins play a crucial role at all levels of integration. These form an initially adsorbed protein layer as early as during the implantation operation and thus, as explained below, since the first cells will later colonize on this layer, determine the further progression of the healing-in of the implant.
In the molecular interaction between implant, also referred to as biomaterial, and tissue, a multitude of reactions take place which seem to be strictly hierarchically ordered. The adsorption of proteins on the surface of the biomaterial is the first biological reaction which takes place. In the resulting protein layer, single protein molecules are for example either transformed by conformational changes to signal substances which are presented on the surface, or protein fragments functioning as signal substances are released by catalytic (proteolytic) reactions. Triggered by the signal substances, cellular colonization takes place in the next phase, and can include a multitude of cells such as leucocytes, macrophages, immunocytes and finally also tissue cells (fibroblasts, fibrocytes, osteoblasts, osteocytes). In this phase other signal substances, so-called mediators such as for example cytokines, chemokines, morphogens, tissue hormones and true hormones play a decisive role. In the case of biocompatibility, there is a final integration of the implant into the entire organism, and one ideally obtains a permanent implant.
In light of work performed in recent years at the molecular level of osteogenesis, chemical signal substances, the so-called “bone morphogenic proteins” (BMP-1-BMP-13), which influence bone growth, have gained increasing importance. BMPs (in particular BMP-2 and BMP-4, BMP-5, BMP-6, BMP-7) are osteoinductive proteins which stimulate the formation of new bones and bone healing by effecting the proliferation and the differentiation of precursor cells to osteoblasts. Furthermore they promote the formation of hormone receptors, bone-specific substances such as collagen type 1, osteocalcin, osteopontin and finally mineralization. Here, the BMP-molecules regulate the three key reactions chemotaxis, mitosis and differentiation of the respective precursor cells. In addition, the BMPs play an important role in embryogenesis, organogenesis of bone and of other tissue, wherein osteoblasts, chondroblasts, myoblasts and vascular smooth muscle cells (proliferation inhibition by BMP-2) are known as target cells.
SUMMARY OF THE INVENTION
A particular aim in the immobilization method according to the invention is a degree of stimulation (that is, surface concentration of the immobilized protein) which allows a multivalent interaction between surface and cell and enables the effective control of bone and tissue formation.
To date, 13 BMPs including multiple isoforms are known. With the exception of BMP-1, the BMPs belong to the “transforming growth factor beta” (TGF-&bgr;) superfamily, for which specific receptors on the surface of the corresponding cells have been found. As the successful use of recombinant human BMP-2 and/or BMP-7 in experiments on defective healing processes in rats, dogs, rabbits and monkeys has shown, no species-specificity seems to exist. Previous attempts to exploit the bone formation-triggering characteristics of the BMPs for implantation purposes, in which BMP-2 and/or BMP-7 were noncovalently applied to metallic or ceramic biomaterials, have however been largely unsuccessful.
The goal of the present invention is to produce improved biomaterials for use as implants.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1
is a photograph showing various substrates with oxidized TiO
2
flakes.
FIG. 2
is a graph showing hysteresis measurements of various surfaces.
FIG. 3
is a graph showing the change in contact angle and hysteresis with non-oxidized titanium flakes following APS-modification and protein coupling.
FIG. 4
is a graph showing the change in contact angle and hysteresis with oxidized titanium flakes following APS-modification and protein coupling.
FIG. 5
is a graph showing the reduction of non-specific adsorption of fibrinogen by agarose coating of quartz glass plates.
REFERENCES:
patent: 5306307 (1994-04-01), Senter et al.
patent: 5837235 (1998-11-01), Mueller et al.
patent: 90/09798 (1990-09-01), None
patent: WO 92/00047 (1992-09-01), None
Fish Robert D.
Morphoplant GmbH
Naff David M.
Rutan & Tucker
LandOfFree
Immobilizing mediator molecules via anchor molecules on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immobilizing mediator molecules via anchor molecules on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immobilizing mediator molecules via anchor molecules on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3167042